JP2022543191A5 - - Google Patents

Info

Publication number
JP2022543191A5
JP2022543191A5 JP2022502227A JP2022502227A JP2022543191A5 JP 2022543191 A5 JP2022543191 A5 JP 2022543191A5 JP 2022502227 A JP2022502227 A JP 2022502227A JP 2022502227 A JP2022502227 A JP 2022502227A JP 2022543191 A5 JP2022543191 A5 JP 2022543191A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
oligonucleotide according
present
multimerized
covalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022502227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543191A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044110 external-priority patent/WO2021021959A2/en
Publication of JP2022543191A publication Critical patent/JP2022543191A/ja
Publication of JP2022543191A5 publication Critical patent/JP2022543191A5/ja
Withdrawn legal-status Critical Current

Links

JP2022502227A 2019-07-30 2020-07-29 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達 Withdrawn JP2022543191A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962880591P 2019-07-30 2019-07-30
US62/880,591 2019-07-30
PCT/US2020/044110 WO2021021959A2 (en) 2019-07-30 2020-07-29 Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity

Publications (2)

Publication Number Publication Date
JP2022543191A JP2022543191A (ja) 2022-10-11
JP2022543191A5 true JP2022543191A5 (cg-RX-API-DMAC7.html) 2023-08-07

Family

ID=74228530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502227A Withdrawn JP2022543191A (ja) 2019-07-30 2020-07-29 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達

Country Status (8)

Country Link
US (1) US20230114023A1 (cg-RX-API-DMAC7.html)
EP (1) EP4004205A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022543191A (cg-RX-API-DMAC7.html)
CN (1) CN114466929A (cg-RX-API-DMAC7.html)
AU (1) AU2020319911A1 (cg-RX-API-DMAC7.html)
CA (1) CA3144467A1 (cg-RX-API-DMAC7.html)
IL (1) IL289801A (cg-RX-API-DMAC7.html)
WO (1) WO2021021959A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
IL316159A (en) 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
CN110248665A (zh) 2017-02-06 2019-09-17 Mpeg La有限责任公司 具有降低的肾清除的多聚体寡核苷酸
WO2021222635A2 (en) 2020-04-30 2021-11-04 Mpeg La, L.L.C. Multimeric oligonucleotides with divided strands
US20230372508A1 (en) * 2022-05-19 2023-11-23 Olix Us, Inc. Linkers coupling functional ligands to macromolecules
JPWO2025100427A1 (cg-RX-API-DMAC7.html) * 2023-11-06 2025-05-15

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
PH12012501596A1 (en) * 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
US20150247141A1 (en) * 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
CA2889044A1 (en) * 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
CA2893801A1 (en) * 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
IL316159A (en) * 2015-06-15 2024-12-01 Mpeg La Llc Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
CN110248665A (zh) * 2017-02-06 2019-09-17 Mpeg La有限责任公司 具有降低的肾清除的多聚体寡核苷酸

Similar Documents

Publication Publication Date Title
US10941400B2 (en) Compounds and methods for enhanced cellular uptake
TWI924663B (zh) 用於抑制PNPLA3表現之RNAi劑、其醫藥組成物及使用方法
EP2611927B1 (en) Novel single chemical entities and methods for delivery of oligonucleotides
JP2024526890A5 (cg-RX-API-DMAC7.html)
JP2021533804A5 (cg-RX-API-DMAC7.html)
TW202609059A (zh) 用於抑制類血管生成素蛋白-3 (ANGPTL3)表現的RNAi藥劑及組合物及使用方法
US20120231069A1 (en) Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
JP6773677B2 (ja) 改善されたジスルフィド含有アルキン連結剤
AU2013262415B2 (en) Oligonucleotide chelate complex methods
JP2020518552A5 (cg-RX-API-DMAC7.html)
JP2024536811A5 (cg-RX-API-DMAC7.html)
BR112020008546A2 (pt) construtos de oligonucleotídeo e usos dos mesmos
JPWO2018003739A1 (ja) 機能的リガンドを含む核酸複合体
WO2017068790A1 (ja) 核酸複合体
JP2017523790A (ja) 代謝障害のためのマイクロrnaの標的化
JP2022543191A (ja) 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達
WO2011130716A2 (en) A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
JP2024528503A5 (cg-RX-API-DMAC7.html)
WO2017068791A1 (ja) 少なくとも1つのバルジ構造を有する核酸複合体
TW202612708A (zh) 組合治療
JP6715775B2 (ja) 非凝集性免疫賦活化オリゴヌクレオチド
JP2023540806A5 (cg-RX-API-DMAC7.html)
JP2023545418A (ja) 一置換ホモ二価リンカーを含むマルチコンジュゲート
JP2023525480A (ja) 分割鎖を有する多量体オリゴヌクレオチド
JP7740708B2 (ja) ポリデオキシアデニル酸が連結した短鎖CpG含有オリゴデオキシヌクレオチド、該オリゴデオキシヌクレオチドを含有する複合体、及びその用途